Meeting
2022 ASCO Annual Meeting
Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
Authors
Jonathan E. Rosenberg
Memorial Sloan Kettering Cancer Center, New York, NY
Jonathan E. Rosenberg , Thomas Powles , Guru P. Sonpavde , Yohann Loriot , Ignacio Duran , Jae-Lyun Lee , Nobuaki Matsubara , Christof Vulsteke , Daniel E. Castellano , Ronac Mamtani , Chunzhang Wu , Maria Matsangou , Mary S. Campbell , Daniel P. Petrylak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03474107
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4516)
DOI
10.1200/JCO.2022.40.16_suppl.4516
Abstract #
4516
Poster Bd #
8
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.
First Author: Ronac Mamtani
Poster
2019 Genitourinary Cancers Symposium
EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).
First Author: Daniel Peter Petrylak
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.
First Author: Sarmad Sadeghi
Poster
2022 ASCO Annual Meeting
A phase III randomized trial of eribulin (E) with or without gemcitabine versus standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.
First Author: Sarmad Sadeghi